Mogamulizumab (Poteligeo®). HTA ID: 20061

Assessment Status NCPE Assessment Process Complete
HTA ID 20061
Drug Mogamulizumab
Brand Poteligeo®
Indication For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.
Assessment Process
Rapid review commissioned 21/12/2020
Rapid review completed 21/01/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/01/2021
Pre-submission consultation with Applicant 23/03/2021
Full submission received from Applicant 07/10/2021
Preliminary review sent to Applicant 22/02/2022
NCPE assessment re-commenced 23/03/2022
Follow-up to preliminary review sent to Applicant 07/04/2022
NCPE assessment re-commenced 19/04/2022
Factual accuracy sent to Applicant 17/06/2022
NCPE assessment re-commenced 24/06/2022
NCPE assessment completed 09/08/2022
NCPE assessment outcome The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations; May 2023